Freeze-Drying Process Optimisation for a Small Molecule - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Freeze-Drying Process Optimisation for a Small Molecule


Pharmaceutical Technology Europe
Volume 24, Issue 6

Acknowledgments

The authors acknowledge Hiltrud Lindenblatt, PhD and senior scientist of life-cycle management CMC management at Merck KGaA, for providing the gentamicin sulphate.

Henning Gieseler* is an assistant professor and group leader in the Freeze-Drying Focus Group, Division of Pharmaceutics, University of Erlangen (Germany) and managing director of Gilyos GmbH, 15 Friedrich-Bergius-Ring, Wuerzburg, Germany, 97076, tel. +49 931 907 05678,
. Susanne Hibler is a graduate student in the Freeze-Drying Focus Group, Division of Pharmaceutics, University of Erlangen.

*To whom all correspondence should be addressed.

Submitted: 22 Mar. 2012; Accepted 23 Mar. 2012.

CITATION: When referring to this article, please cite it as "Henning Gieseler And Susanne Hibler, "Freeze-Drying Process Optimization for a Small Molecule," Pharmaceutical Technology, 36(6) (2012).

References

1. S. Rambhatla and M.J. Pikal, "Heat and Mass Transfer Issues in Freeze-drying Process Development," in Lyophilization of Biopharmaceuticals, H. R. Constantino and M.J. Pikal, Eds. (American Association of Pharmaceutical Scientists, Arlington, 1st ed., 2004), pp 75–109.

2. X. Tang and M.J. Pikal, Pharm. Res. 21 (2), 191–200 (2004).

3. M.J. Pikal and S. Shah, Int. J. Pharm. 62 (2-3), 165–186 (1990).

4. J.F. Carpenter et al., Pharm. Res. 14 (8), 969–975 (1997).

5. R.E. Johnson et al., J. Pharm. Sci. 99 (6), 2863–2873 (2010).

6. D.E. Overcashier, T.W. Patapoff, and C.C. Hsu, J. Pharm. Sci. 88 (7), 688–695 (1999).

7. J.D. Colandene et al. J. Pharm. Sci. 96 (6), 1598–1608 (2007).

8. E. Meister and H. Gieseler, J. Pharm. Sci. 98 (9), 3072–3087 (2009).

9. L.M. Her and S.L. Nail, Pharm. Res. 11 (1), 54–59 (1994).

10. J. Liu, Pharm. Dev. Technol. 11 (1), 3–28 (2006).

11. E. Meister, Methodology, Data Interpretation and Practical Transfer of Freeze-Dry Microscopy, PhD. Thesis, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen (2009).

12. F. Fonseca et al., Biotechnol. Prog. 20 (1), 229–238 (2004).

13. M.J. Pikal, J. Parenter. Sci. Technol. 39 (3), 115–139 (1985).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here